1. Home
  2. HLNE vs BLCO Comparison

HLNE vs BLCO Comparison

Compare HLNE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLNE
  • BLCO
  • Stock Information
  • Founded
  • HLNE 1991
  • BLCO 1853
  • Country
  • HLNE United States
  • BLCO Canada
  • Employees
  • HLNE N/A
  • BLCO N/A
  • Industry
  • HLNE Investment Managers
  • BLCO Ophthalmic Goods
  • Sector
  • HLNE Finance
  • BLCO Health Care
  • Exchange
  • HLNE Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • HLNE 7.6B
  • BLCO 7.0B
  • IPO Year
  • HLNE 2017
  • BLCO 2022
  • Fundamental
  • Price
  • HLNE $150.58
  • BLCO $17.86
  • Analyst Decision
  • HLNE Hold
  • BLCO Buy
  • Analyst Count
  • HLNE 9
  • BLCO 12
  • Target Price
  • HLNE $160.50
  • BLCO $20.91
  • AVG Volume (30 Days)
  • HLNE 557.6K
  • BLCO 529.2K
  • Earning Date
  • HLNE 02-04-2025
  • BLCO 02-19-2025
  • Dividend Yield
  • HLNE 1.27%
  • BLCO N/A
  • EPS Growth
  • HLNE 51.92
  • BLCO N/A
  • EPS
  • HLNE 4.63
  • BLCO N/A
  • Revenue
  • HLNE $648,658,000.00
  • BLCO $4,684,000,000.00
  • Revenue This Year
  • HLNE $23.71
  • BLCO $17.39
  • Revenue Next Year
  • HLNE $8.88
  • BLCO $6.18
  • P/E Ratio
  • HLNE $32.53
  • BLCO N/A
  • Revenue Growth
  • HLNE 31.90
  • BLCO 18.01
  • 52 Week Low
  • HLNE $103.42
  • BLCO $13.16
  • 52 Week High
  • HLNE $203.72
  • BLCO $21.69
  • Technical
  • Relative Strength Index (RSI)
  • HLNE 18.03
  • BLCO 35.71
  • Support Level
  • HLNE $148.65
  • BLCO $17.57
  • Resistance Level
  • HLNE $196.95
  • BLCO $18.99
  • Average True Range (ATR)
  • HLNE 5.32
  • BLCO 0.50
  • MACD
  • HLNE -3.19
  • BLCO -0.16
  • Stochastic Oscillator
  • HLNE 4.63
  • BLCO 9.24

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private market investment solutions provider in the United States. It works with its clients to conceive, structure, build out, manage and monitor portfolios of private markets funds and direct investments, and it helps them access a set of such investment opportunities around the world. The company offers a range of investment solutions across a range of private markets, including private equity, private credit, real estate, infrastructure, natural resources, growth equity, venture capital and impact. The company generate revenues mainly from management and advisory fees.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: